bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Data File 2 from Perceived Appropriateness of Assessing for Health-related Socioeconomic Risks Among Adult Patients with Cancer
Authors: Vu Milkie , Boyd Kelly , De Marchis Emilia H. , Garnache Bridgette G. , Gottlieb Laura M. , Gross Cary P. , Lee Nita K. , Lindau Stacy Tessler , Mun Sophia , Winslow Victoria A. , Makelarski Jennifer A.
Published: April 2023

Sociodemographic and healthcare factors in relation to recruitment sites of patients with cancer (N=154)
Data from Perceived Appropriateness of Assessing for Health-related Socioeconomic Risks Among Adult Patients with Cancer
Authors: Vu Milkie , Boyd Kelly , De Marchis Emilia H. , Garnache Bridgette G. , Gottlieb Laura M. , Gross Cary P. , Lee Nita K. , Lindau Stacy Tessler , Mun Sophia , Winslow Victoria A. , Makelarski Jennifer A.
Published: April 2023

Cancer treatment can trigger or exacerbate health-related socioeconomic risks (HRSR; food/housing insecurity, transportation/utilities difficulties, and interpersonal violence). The American Cancer Society and National Cancer Institute recommend HRSR screening and referral, but little research has examined the perceptions of patients with cancer on the appropriateness of HRSR screening in healthcare settings. We examined whether HRSR status, desire for assistance with HRSRs, and sociodemographic and health care–related factors were associated with perceived appropriateness of HRSR screening in health care settings and comfort with HRSR documentation in electronic health records (EHR). A convenience sample of adult patients with cancer at two outpatient clinics completed self-administered surveys. We used χ2 and Fisher exact tests to test for significant associations. The sample included 154 patients (72% female, 90% ages 45 years or older). Thirty-six percent reported ≥1 HRSRs and 27% desired assistance with HRSRs. Overall, 80% thought it was appropriate to assess for HRSRs in health care settings. The distributions of HRSR status and sociodemographic characteristics were similar among people who perceived screening to be appropriate and those who did not. Participants who perceived screening as appropriate were three times as likely to report prior experience with HRSR screening (31% vs. 10%, P = 0.01). Moreover, 60% felt comfortable having HRSRs documented in the EHR. Comfort with EHR documentation of HRSRs was significantly higher among patients desiring assistance with HRSRs (78%) compared with those who did not (53%, P < 0.01). While initiatives for HRSR screening are likely to be seen by patients with cancer as appropriate, concerns may remain over electronic documentation of HRSRs.
Significance:
National organizations recommend addressing HRSRs such as food/housing insecurity, transportation/utilities difficulties, and interpersonal violence among patients with cancer. In our study, most patients with cancer perceived screening for HRSRs in clinical settings as appropriate. Meanwhile, concerns may remain over the documentation of HRSRs in EHRs.
Successful Treatment of Prurigo Nodularis by Dupilumab: Report of 24 Patients
Authors: Gao Zirui , Dou Yuanqing , Zhao Pei , Wang Caroline J , Zhang Jianzhong
Published: April 2023

Background: Prurigo nodularis (PN) is a chronic pruritic skin disease which is difficult to treat. Current treatment options often lead to limited clinical benefit or severe side effects. Objective: The objective of this study was to evaluate the efficacy and safety of dupilumab in the treatment of PN in adults. Method: This study is a retrospective cohort study. Twenty-four adult patients with PN were included and treated with dupilumab. The primary outcomes were the mean reduction in the Investigator’s Global Assessment (IGA) score and pruritus numeric rating scale (p-NRS) score. Outcomes were assessed at baseline, week 4, week 16, and week 36. Results: The study included 24 patients, of whom 9 (37.5%) were male, and the mean (SD) age of the enrolled patients was 49.88 ± 16.71 years. At the end of the 16-week treatment, the mean p-NRS score decreased from 7.50 ± 2.21 to 1.41 ± 0.91 (p < 0.001), sleeplessness numeric rating scale (s-NRS) score declined from 5.33 ± 3.29 to 0.18 ± 0.59 (p < 0.001), and Dermatology Life Quality Index (DLQI) score decreased from 13.32 ± 4.88 to 0.91 ± 0.81 (p < 0.001). Fourteen (63.6%) of 22 patients achieved IGA 0/1 and 21 (95.5%) patients achieved IGA activity 0/1. Among 14 patients who achieved IGA 0/1, 10 had an elevated serum IgE level, and patients with a high serum IgE level showed a more remarkable reduction in IGA (r = 0.52, p = 0.03). Patients with AD responded faster than those without AD (3.76 ± 1.71 weeks vs. 6.40 ± 1.67 weeks, p = 0.01). Adverse events were recorded in 4/24 (16.6%) patients, with conjunctivitis being the most frequent. Conclusion: This study demonstrated that dupilumab is effective and safe for PN and could be a potential therapeutic option.